Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 7/20 | 0.32 |
| ▸ | HTR2B | P41595 | 7/20 | 0.32 |
| ▸ | HTR2A | P28223 | 6/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4527945 | 0.93 | SCN9A (0.36) | TRPA1SCN9AHTR2CHTR2BHTR2A | |
| SCHEMBL4517522 | 0.89 | ALOX5AP (0.36) | SCN9A | |
| SCHEMBL4535079 | 0.86 | PTPN1 (0.37) | SCN9APTPN1HTR2CHTR2BHTR2A | |
| SCHEMBL4514041 | 0.84 | NR1H2 (0.38) | SCN9AHTR2CHTR2BHTR2A | |
| SCHEMBL4528908 | 0.84 | TRPA1 (0.44) | TRPA1SCN9AHSD11B1 | |
| SCHEMBL4533710 | 0.83 | PTPN1 (0.41) | SCN9APTPN1HTR2CHTR2BHTR2A | |
| SCHEMBL4524964 | 0.83 | CTSS (0.35) | TRPA1SCN9AHTR2CHTR2BHTR2A | |
| SCHEMBL4531452 | 0.83 | HTR2A (0.31) | HTR2CHTR2BHTR2A | |
| SCHEMBL4524489 | 0.81 | AR (0.40) | SCN9AHTR2CHTR2BHTR2A | |
| SCHEMBL3732360 | 0.80 | PTPN1 (0.45) | TRPA1SCN9APTPN1HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | claimed |
| EP-1812409-A1 | AMINOQUINAZOLINES COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2007-08-01 | — | — | EP | claimed |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2006-09-21 | — | — | US | claimed |
| WO-2006050843-A1 | AMINOQUINAZOLINES COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-18 | — | — | WO | claimed |
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | BERTHEL STEVEN JOSEPH | 2009-04-23 | — | — | US | disclosed |
| EP-1812409-A1 | AMINOQUINAZOLINES COMPOUNDS | F. Hoffmann-Roche AG (CH) | 2007-08-01 | — | — | EP | disclosed |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | BERTHEL STEVEN J | 2006-09-21 | — | — | US | disclosed |
| WO-2006050843-A1 | AMINOQUINAZOLINES COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105477-A1 | Quinazoline Protein Tyrosine Phosphatase Inhibitors | PTPN5, PTPN1, PTPN7 | TRPA1 2889/4885SCN9A 1783/4885PTPN1 2/4885 |
| US-20060211715-A1 | Quinazoline protein tyrosine phosphatase inhibitors | PTPN5, PTPN1, PTPN7 | TRPA1 2889/4885SCN9A 1783/4885PTPN1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.